Table 2

Mendelian randomization (MR) estimates between accelerometer-based vigorous PA (fraction of accelerations>425 milli-gravities) and type 2 diabetes and glycemic traits

MethodNo. of SNPsOR/beta95% CIP valueOutcome
Inverse variance weighted (multiplicative random effects)80.83(0.56 to 1.232)0.357Type 2 diabetes
Weighted median80.80(0.58 to 1.11)0.177Type 2 diabetes
MR-PRESSO: outlier corrected60.86(0.60 to 1.21)0.421Type 2 diabetes
MRMix81.45(0.86 to 2.44)0.165Type 2 diabetes
Inverse variance weighted (multiplicative random effects)6−0.018(−0.085 to 0.05)0.606HbA1c
Weighted median60.016(−0.07 to 0.102)0.717HbA1c
MR-PRESSO: raw6−0.018(−0.079 to 0.043)0.595HbA1c
MRMix6−0.035(−0.169 to 0.099)0.609HbA1C
Inverse variance weighted (multiplicative random effects)60.065(−0.11 to 0.24)0.469Fasting glucose
Weighted median60.059(−0.148 to 0.266)0.578Fasting glucose
MR-PRESSO: raw60.065(−0.11 to 0.24)0.502Fasting glucose
MRMix6−0.010(−0.574 to 0.554)0.972Fasting glucose
Inverse variance weighted (multiplicative random effects)60.069(−0.071 to 0.209)0.336HOMA-B
Weighted median60.013(−0.17 to 0.197)0.886HOMA-B
MR-PRESSO: raw60.069(−0.071 to 0.209)0.380HOMA-B
MRMix60.110(−0.902 to 1.122)0.831HOMA-B
Inverse variance weighted (multiplicative random effects)60.102(−0.111 to 0.316)0.349HOMA-IR
Weighted median6−0.041(−0.258 to 0.176)0.708HOMA-IR
MR-PRESSO: raw60.102(−0.111 to 0.316)0.392HOMA-IR
MRMix6−0.030(−0.455 to 0.395)0.890HOMA-IR
  • HbA1c, hemoglobin A1c; HOMA-B, homeostasis model assessment of beta-cell function; HOMA-IR, homeostasis model assessment of insulin resistance ; MR-PRESSO, MR-Pleiotropy RESidual Sum and Outlier; PA, physical activity; SNPs, single nucleotide polymorphisms.